News

Aug 27, 2023

CHOSA Oncology AB’s postpones publication of the interim report Q2

Regulatory press release: CHOSA Oncology announced today, 27[th] August 2023, the decision to postpone the release of its interim report for the second quarter of 2023. The previously communicated publication date of Monday,...[Read more]

Older news

Jun 30, 2023

ASCO 2023 - good news for CHOSA

· Immuno Oncology with PD1 inhibitors successful in NSCLC in combination with cisplatin. · CHOSA’s DRP has the potentia...[Read more]

Jun 03, 2023

CHOSA Oncology AB publishes results from clinical phase 2 trial of liposomal formulation in breast cancer, using predictive marker for cisplatin

Regulatory press release: [Read more]

May 26, 2023

Bulletin from the annual general meeting on 26 May 2023 in Chosa Oncology AB

Regulatory press release: The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English transla...[Read more]

May 25, 2023

CHOSA Oncology AB presents clinical phase 2 results of LiPlaCis and its Drug Response Predictor test at ASCO 2023

Regulatory press release: CHOSA Oncology AB today publishes results from the prospective phase 2 study of LiPlaCis® (a liposomal formulation of cispla...[Read more]

May 16, 2023

CHOSA Oncology AB out-license clinical-stage cancer vaccine candidate to Magle Group

Regulatory press release: CHOSA Oncology AB, today announces that the company has out-licensed the clinical-stage therapeutic cancer vaccine candidate...[Read more]

May 03, 2023

CHOSA Oncology AB announces approved re-listing memorandum

Regulatory press release: CHOSA Oncology AB (publ) (CHOSA or the Company), formerly RhoVac, announces that Spotlight Stock Market (Spotlight) today ap...[Read more]

May 03, 2023

CHOSA Oncology AB publishes annual report 2022

Regulatory press release: CHOSA Oncology AB (publ) announces today that the company is publishing its annual report for 2022. The annual report has be...[Read more]

Apr 25, 2023

Notice of annual general meeting in Chosa Oncology AB

Regulatory press release: The shareholders of Chosa Oncology AB, Reg. No. 559037-2271, are invited to attend the annual general meeting to be held on...[Read more]

Apr 20, 2023

CHOSA Oncology AB payback of convertible loan in process - update

Regulatory press release: CHOSA Oncology AB has as previously announced initiated the process of payback of the convertible loan of 14,98 mSEK (plus i...[Read more]

Apr 18, 2023

CHOSA Oncology AB payback of convertible loan in process

Regulatory press release: CHOSA Oncology AB has initiated the process of payback of the convertible loan of 14,98 mSEK (plus interest) which RhoVac ob...[Read more]

Apr 11, 2023

CHOSA Oncology AB's abstract Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer accepted at 2023 ASCO Annual Meeting

Regulatory press release: CHOSA Oncology a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DR...[Read more]

Apr 08, 2023

RhoVac AB (under name change to Chosa Oncology AB) has completed the acquisition of Chosa ApS and a new board and CEO have taken office

Regulatory press release: RhoVac AB (under name change to Chosa Oncology AB) (“RhoVac or the “Company) has today completed the acquisition of the Dani...[Read more]

News published before 2023 >>